OPDP slaps Gilead with Untitled Letter

Share this article:
Gilead shows latest on GT-1 all-oral
OPDP slaps Gilead with Untitled Letter

Less than a month after FDA's draft guidance for digital and social media was released, Gilead has kindly showed the industry how not to advertise a drug on Google AdWords.

OPDP slapped the drugmaker with an untitled letter today over promotional efforts for its hepatitis B treatment Viread, stating the ad (pictured below) omitted the drug's established name, failed to communicate any risk information, and misbranded the product.

Within the 15 pages of guidelines released last month, the agency suggested benefit and risk information be treated equally in character-limiting services (Twitter/AdWords)—saying the two should be juxtaposed to offer consumers balanced information. Gilead did not include any risk information, however.

The agency also charged Gilead's advertising and promotion arm with “providing evidence that Viread is intended for a new use for which it lacks approval, and for which its labeling does not provide adequate directions for use.” Namely, the ad states Viread prevents hepatitis B, while the drug is only approved as a treatment for patients who have the disease.

Gilead was also faulted for not using the chemical name for Viread—tenofovir disoproxil.

And while OPDP didn't raise this point in its letter, in FDA's draft guidance the regulator also stated that risk information should be linked as well—another guideline Gilead neglected to address.

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union